29 Both once-daily (QD) and twice-daily (BID) mometasone furoate (MF) provide additional improvement in patients previously maintained on short-acting inhaled beta2-agonists
KEMP, JVolume:
105
Language:
english
Journal:
Journal of Allergy and Clinical Immunology
DOI:
10.1016/s0091-6749(00)90461-5
Date:
January, 2000
File:
PDF, 143 KB
english, 2000